ASH 2022 | Outcomes of patients with double-hit lymphoma treated with CAR-T therapy
Gareth Gregory
• 11 Dec 2022
In this video, Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, highlights a study investigating whether CAR-T therapy could be used to overcome the adverse prognosis associated with double-hit lymphoma (DHL). Results demonstrated that patients with DHL responded to CAR-T therapy equally as well as non-DHL patients, which represents a major paradigm shift in this patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
